Compare INO & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INO | SPRO |
|---|---|---|
| Founded | 1979 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.1M | 129.6M |
| IPO Year | 1998 | 2017 |
| Metric | INO | SPRO |
|---|---|---|
| Price | $1.58 | $2.33 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 344.4K |
| Earning Date | 03-17-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $182,337.00 | ★ $40,549,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23,060.18 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.30 | $0.51 |
| 52 Week High | $2.98 | $3.22 |
| Indicator | INO | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 43.10 | 50.55 |
| Support Level | $1.54 | $2.28 |
| Resistance Level | $1.78 | $2.43 |
| Average True Range (ATR) | 0.11 | 0.12 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 32.79 | 65.38 |
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.